EPO published patent application EP3727348A1 on March 25, 2026, filed by Flamel Ireland Limited. The patent covers modified release gamma-hydroxybutyrate formulations with improved stability, invented by Hervé Guillard. The invention is classified under A61K 9/50 (nanoparticle formulations) and A61K 31/19 (carboxylic acid derivatives). The designation extends to 44 European states including all EU member states, EFTA countries, and the UK.

Pharmaceutical companies developing or commercializing modified release GHB formulations should conduct a freedom-to-operate analysis to assess potential infringement risks. The patent provides Flamel Ireland with exclusive rights to the claimed formulations in designated states for the standard 20-year patent term from filing. No immediate regulatory compliance actions are required as this is a patent publication rather than a new regulatory requirement.